MedPath

Moxifloxacin

Generic Name
Moxifloxacin
Brand Names
Avelox, Moxeza, Vigamox
Drug Type
Small Molecule
Chemical Formula
C21H24FN3O4
CAS Number
151096-09-2
Unique Ingredient Identifier
U188XYD42P
Background

Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Indication

For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions
Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
Clinical Trials
Related News

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Placebo
First Posted Date
2022-02-15
Last Posted Date
2023-05-15
Lead Sponsor
Mitsubishi Tanabe Pharma America Inc.
Target Recruit Count
29
Registration Number
NCT05241535
Locations
🇺🇸

Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States

🇺🇸

Dallas Clinical Research Unit, Dallas, Texas, United States

A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2022-01-14
Last Posted Date
2022-03-04
Lead Sponsor
Concert Pharmaceuticals
Target Recruit Count
48
Registration Number
NCT05192369
Locations
🇺🇸

Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial

Phase 2
Conditions
Moxifloxacin
Post-Traumatic Endophthalmitis
Endophthalmitis
Open Globe Injury
Interventions
First Posted Date
2021-12-17
Last Posted Date
2021-12-17
Lead Sponsor
University of Campinas, Brazil
Target Recruit Count
100
Registration Number
NCT05162625
Locations
🇧🇷

University of Campinas, Campinas, Brazil

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

Phase 3
Active, not recruiting
Conditions
Acanthamoeba Keratitis
Fungal Keratitis
Interventions
Other: Placebo
First Posted Date
2021-11-05
Last Posted Date
2025-01-31
Lead Sponsor
University of California, San Francisco
Target Recruit Count
330
Registration Number
NCT05110001
Locations
🇮🇳

Aravind Eye Care System, Madurai, Tamil Nadu, India

🇧🇷

Federal University of São Paulo, São Paulo, Brazil

Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis

Phase 4
Conditions
Endophthalmitis
Trauma, Corneal
Interventions
Drug: Intraocular Instillation Solution
First Posted Date
2021-10-15
Last Posted Date
2021-11-10
Lead Sponsor
Federal University of São Paulo
Target Recruit Count
100
Registration Number
NCT05079854
Locations
🇧🇷

Dept of Ophthalmology - UNIFESP/Hospital São Paulo, São Paulo, SP, Brazil

Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants

Phase 4
Completed
Conditions
Healthy
Interventions
Drug: Oral Placebo
Drug: SC Placebo
First Posted Date
2021-09-16
Last Posted Date
2024-05-03
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
Target Recruit Count
77
Registration Number
NCT05046132
Locations
🇺🇸

Parexel Early Phase Clinical Unit (Los Angeles), Glendale, California, United States

Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients

Active, not recruiting
Conditions
Tuberculosis, Pulmonary
Interventions
First Posted Date
2021-09-16
Last Posted Date
2024-01-05
Lead Sponsor
Tuberculosis Research Centre, India
Target Recruit Count
550
Registration Number
NCT05047055
Locations
🇮🇳

National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India

Complications After Lower Third Molar Surgery

Not Applicable
Conditions
Antibiotic Side Effect
Antibiotic Resistant Infection
Infection, Laboratory
Postoperative Complications
Antibiotic Reaction
Antibiotic Resistant Strain
Infection, Bacterial
Interventions
Other: Placebo
First Posted Date
2021-08-30
Last Posted Date
2022-06-15
Lead Sponsor
University of Novi Sad
Target Recruit Count
157
Registration Number
NCT05027893
Locations
🇷🇸

Dental Clinic of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Vojvodina, Serbia

A Study of the Cardiac Effects of Danicopan in Healthy Adults

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Moxifloxacin-matching Placebo
Drug: Danicopan-matching placebo
First Posted Date
2021-08-23
Last Posted Date
2021-08-23
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
33
Registration Number
NCT05016206
Locations
🇺🇸

Clinical Trial Site, Tempe, Arizona, United States

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

Early Phase 1
Completed
Conditions
Hyperuricemia
Gout
Qt Interval, Variation in
Interventions
Drug: LC350189 200mg
Drug: Placebo
Drug: LC350189 600mg
First Posted Date
2021-07-19
Last Posted Date
2022-01-06
Lead Sponsor
LG Chem
Target Recruit Count
37
Registration Number
NCT04966325
Locations
🇺🇸

PPD, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy